Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics

BACKGROUND: Many repurposed drugs have progressed rapidly to Phase 2 and 3 trials in COVID19 without characterisation of Pharmacokinetics /Pharmacodynamics including safety data. One such drug is nafamostat mesylate. METHODS: We present the findings of a phase Ib/IIa open label, platform randomised...

Descripción completa

Detalles Bibliográficos
Autores principales: Quinn, Tom M., Gaughan, Erin E., Bruce, Annya, Antonelli, Jean, O'Connor, Richard, Li, Feng, McNamara, Sarah, Koch, Oliver, MacKintosh, Claire, Dockrell, David, Walsh, Timothy, Blyth, Kevin G., Church, Colin, Schwarze, Jürgen, Boz, Cecilia, Valanciute, Asta, Burgess, Matthew, Emanuel, Philip, Mills, Bethany, Rinaldi, Giulia, Hardisty, Gareth, Mills, Ross, Findlay, Emily Gwyer, Jabbal, Sunny, Duncan, Andrew, Plant, Sinéad, Marshall, Adam D.L., Young, Irene, Russell, Kay, Scholefield, Emma, Nimmo, Alastair F., Nazarov, Islom B., Churchill, Grant C., McCullagh, James S.O., Ebrahimi, Kourosh H., Ferrett, Colin, Templeton, Kate, Rannard, Steve, Owen, Andrew, Moore, Anne, Finlayson, Keith, Shankar-Hari, Manu, Norrie, John, Parker, Richard A., Akram, Ahsan R., Anthony, Daniel C., Dear, James W., Hirani, Nik, Dhaliwal, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831100/
https://www.ncbi.nlm.nih.gov/pubmed/35152152
http://dx.doi.org/10.1016/j.ebiom.2022.103856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831100/
https://www.ncbi.nlm.nih.gov/pubmed/35152152
http://dx.doi.org/10.1016/j.ebiom.2022.103856

Ejemplares similares